Pulmonary surfactant in respiratory syncytial virus bronchiolitis: The role in pathogenesis and clinical implications

Pediatric Pulmonology

Volumn 46, Issue 5, 2011, Pages 415-420

  Barreira, Eliane Roseli ^a,c   Precioso, Alexander Roberto ^a,b   Bousso, Albert ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO BUTANTAN   (Brazil)

^c NONE   (Brazil)

Author keywords

bronchiolitis; human; pulmonary surfactants; respiratory syncytial virus

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 2; SURFACTANT PROTEIN A; SURFACTANT PROTEIN D; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; LUNG SURFACTANT;

ADAPTIVE IMMUNITY; ARTICLE; ASTHMA; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; HEMOSTASIS; HUMAN; INFLAMMATION; INNATE IMMUNITY; LUNG MECHANICS; PATHOGENESIS; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; RESPIRATORY SYNCYTIAL VIRUS BRONCHIOLITIS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIRAL BRONCHIOLITIS; VIRAL CLEARANCE; WHEEZING; ANIMAL; BRONCHIOLITIS; IMMUNOLOGY; LUNG;

ANIMALS; BRONCHIOLITIS; HUMANS; LUNG; PULMONARY SURFACTANT-ASSOCIATED PROTEIN A; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; PULMONARY SURFACTANTS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 79954483603     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.21395     Document Type: Article

References (57)

1. Yorita KL, Holman RC, Sejvar JJ, Steiner CA, Schonberger LB,. Infectious disease hospitalizations among infants in the United States. Pediatrics 2008; 121: 244-252. (Pubitemid 351198445)
2. Glezen WP, Denny FW,. Epidemiology of acute lower respiratory-disease in children. N Engl J Med 1973; 288: 498-505.
3. Ochoa Sangrador C, Gonzales de Dios J,. Grupo de Revision del Proyecto ABREVIDADo (BRonquiolitis-Estudio de Variabilidad, Idoneidad y Adecuacion). An Pediatr (Barc) 2010; 72: 222.e1-222.e26. Epub 2010 Feb 13.
4. Leader S, Kohlhase K,. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr 2003; 143: S127-S132. (Pubitemid 37456910)
5. Carroll KN, Gebretsadik T, Griffin MR, Wu P, Dupont WD, Mitchel EF, Enriquez R, Hartert TV,. Increasing burden and risk factors for bronchiolitis-related medical visits in infants enrolled in a state health care insurance plan. Pediatrics 2008; 122: 58-64.
6. World Health Organization. Acute respiratory infections (Update February 2009).
7. Welliver RC, Checchia PA, Bauman JH, Fernandes AW, Mahadelvia PJ, Hall CB,. Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children. Curr Med Res Opin 2010; 26: 2175-2181.
8. Wang EEL, Law BJ, Boucher FD, Stephens D, Robinson JL, Dobson S, Langley JM, McDonald J, MacDonald NE, Mitchell I,. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of admission and management variation in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 1996; 129: 390-395. (Pubitemid 27484145)
9. Bonnet D, Schmaltz AA, Feltes TE,. Infection by the respiratory syncytial virus in infants and young children at high risk. Cardiol Young 2005; 15: 256-265. (Pubitemid 41388052)
10. Sigurs N, Aljassim F, Kjellman B,. Asthma and allergy patterns over 18 years after severe bronchiolitis in the first year of life. Thorax 2010 Jun 27 (Epub ahead of print).
11. The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from Respiratory Syncytial Virus infection in high-risk infants. Pediatrics 1998; 102: 531-537.
12. Carbonell-Estrany X, Simoes EAF, Dagan R, Hall CB, Harris B, Hultquist M, Connor EM, Losonsky GA, Motavizumab Study Group. Motavizumab for prophylaxis of Respiratory Syncytial Virus in high-risk children: a noninferiority trial. Pediatrics 2010; 125: E35-E51.
13. Zorc JJ, Hall CB,. Bronchiolitis: recent evidence on diagnosis and management. Pediatrics 2010; 125: 342-349.
14. Ventre K, Randolph AG,. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database of Syst Rev 2007; 24.
15. Davison C, Ventre K, Luchetti M, Randolph A,. Efficacy of interventions for bronchiolitis in critically ill infants: a systematic review and meta-analysis. Pediatr Crit Care Med 2004; 5: 482-489.
16. Whitsett JA, Weaver TE,. Mechanisms of disease: hydrophobic surfactant proteins in lung function and disease. N Engl J Med 2002; 347: 2141-2148. (Pubitemid 36015127)
17. Enhorning G,. Surfactant in airway disease. Chest 2008; 133: 975-980. (Pubitemid 351536875)
18. Sano H, Kuroki Y,. The lung collectins, SP-A and SP-D, modulate pulmonary innate immunity. Mol Immunol 2005; 42: 279-287. (Pubitemid 39626759)
19. LeVine AM, Whitsett JA,. Pulmonary collectins and innate host defense of the lung. Microbes Infect 2001; 3: 161-166. (Pubitemid 32209333)
20. Kishore U, Greenhough TJ, Waters P, Shrive AK, Ghai R, Kamran MF, Bernal AL, Reid KBM, Madan T, Chakraborty T,. Surfactant proteins SP-A and SP-D: structure, function and receptors. Mol Immunol 2006; 43: 1293-1315. (Pubitemid 43356370)
21. van de Wetering JK, van Golde LMG, Batenburg JJ,. Collections-players of the innate immune system. Eur J Biochem 2004; 271: 1229-1249.
22. Wright JR,. Immunoregulatory functions of surfactant proteins. Nat Rev Immunol 2005; 5: 58-68. (Pubitemid 40070331)
23. LeVine AM, Bruno MD, Huelsman KM, Ross GF, Whitsett JA, Korfhagen TR,. Surfactant protein A-deficient mice are susceptible to group streptococcal infection. J Immunol 1997; 158: 4336-4340. (Pubitemid 127483935)
24. LeVine AM, Whitsett JA, Gwozdz JA, Richardson TR, Fisher JH, Burhans MS, Korfhagen TR,. Distinct effects of surfactant protein A or D deficiency during bacterial infection on the lung. J Immunol 2000; 165: 3934-3940. (Pubitemid 32057302)
25. LeVine AM, Kurak KE, Bruno MD, Stark JM, Whitsett JA, Korfhagen TR,., Surfactant protein-A-deficient mice are susceptible to Pseudomonas aeruginosa infection. Am J Respir Cell Mol Biol 1998; 19: 700-708. (Pubitemid 128354253)
26. Linke MJ, Harris CE, Korfhagen TR, McCormack FX, Ashbaugh AD, Steele P, Whitsett JA, Walzer PD,. Immunosuppressed surfactant protein A-deficient mice have increased susceptibility to Pneumocystis carinii infection. Am J Infect Dis 2001; 183: 943-952. (Pubitemid 32207064)
27. LeVine AM, Whitsett JA, Hartshorn KL, Crouch EC, Korfhagen TR,. Surfactant protein D enhances clearance of influenza A virus from the lung in vivo. J Immunol 2001; 167: 5868-5873. (Pubitemid 33062780)
28. Griese M, Steinecker M, Schumacher S, Braun A, Lohse P, Heinrich S,. Children with absent surfactant protein D in bronchoalveolar lavage have more frequently pneumonia. Pediatr Allergy Immunol 2008; 19: 639-647.
29. LeVine A, Gwozdz J, Stark J, Bruno M, Whitsett J, Korfhagen T,. Surfactant protein-A enhances respiratory syncytial virus clearance in vivo. J Clin Invest 1999; 103: 1015-1021. (Pubitemid 29169609)
30. Borron P, McIntosh JC, Korfhagen TR, Whitsett JA, Taylor J, Wright JR,. Surfactant-associated protein A inhibits LPS-induced cytokine and nitric oxide production in vivo. Am J Physiol Lung Cell Mol Physiol 2000; 278: L840-L847. (Pubitemid 30220046)
31. Haczku A,. Protective role of the lung collectins surfactant protein A and surfactant protein D in airway inflammation. J Allergy Clin Immunol 2008; 122: 861-879.
32. Chiba H, Piboonpocanun S, Mitsuzawa H, Kuronuma K, Murphy RC, Voelker DR,. Pulmonary surfactant proteins and lipids as modulators of inflammation and innate immunity. Respirology 2006; 11: S2-S6.
33. Gardai SJ, Xiao YQ, Dickinson M, Nick JA, Voelker DR, Greene KE, Henson PM,. By binding SIRP alpha or calreticulin/CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation. Cell 2003; 115: 1 13-23. (Pubitemid 37255314)
34. Krishnan S, Halonen M, Welliver RC,. Innate immune responses in respiratory syncytial virus infections. Viral Immunol 2004; 17: 220-233. (Pubitemid 38880423)
35. Liu P, Jamaluddin M, Li K, Garofalo R, Casola A, Brasier A,. Retinoic acid-inducible gene I mediates early antiviral response and Toll-like receptor 3 expression in respiratory syncytial virus-infected airway epithelial cells. J Virol 2007; 81: 1401-1411. (Pubitemid 46167861)
36. Harris J, Werling D,. Binding and entry of respiratory syncytial virus into host cells and initiation of the innate immune response. Cell Microbiol 2003; 5: 671-680. (Pubitemid 37185044)
37. Barr F, Pedigo H, Johnson T, Shepherd V,. Surfactant protein-A enhances uptake of respiratory syncytial virus by monocytes and U937 macrophages. Am J Respir Cell Mol Biol 2000; 23: 586-592.
38. Ghildyal R, Hartley C, Varrasso A, Meanger J, Voelker D, Anders E, Mills J,. Surfactant protein A binds to the fusion glycoprotein of respiratory syncytial virus and neutralizes virion infectivity. J Infect Dis 1999; 180: 2009-2013.
39. Nakamura M, Chu HW, Nakamura T, Evans A, Chan ED, Voelker DR,. Anionic pulmonary surfactant lipids suppress Respiratory Syncytial Virus infection. Proc Am Thorac Soc 2009; 6: 322.
40. LeVine A, Elliott J, Whitsett J, Srikiatkhachorn A, Crouch E, DeSilva N, Korfhagen T,. Surfactant protein-d enhances phagocytosis and pulmonary clearance of respiratory syncytial virus. Am J Respir Cell Mol Biol 2004; 31: 193-199. (Pubitemid 39095448)
41. Hickling T, Bright H, Wing K, Gower D, Martin S, Sim R, Malhotra R,. A recombinant trimeric surfactant protein D carbohydrate recognition domain inhibits respiratory syncytial virus infection in vitro and in vivo. Eur J Immunol 1999; 29: 3478-3484. (Pubitemid 29527795)
42. LeVine A, Lotze A, Stanley S, Stroud C, O'Donnell R, Whitsett J, Pollack M,. Surfactant content in children with inflammatory lung disease. Crit Care Med 1996; 24: 1062-1067. (Pubitemid 26189951)
43. Schmidt R, Markart P, Ruppert C, Wygrecka M, Kuchenbuch T, Walmrath D, Seeger W, Guenther A,. Time-dependent changes in pulmonary surfactant function and composition in acute respiratory distress syndrome due to pneumonia or aspiration. Respir Res 2007; 8: 55.
44. Van Schaik S, Vargas I, Welliver R, Enhorning G,. Surfactant dysfunction develops in BALB/c mice infected with respiratory syncytial virus. Pediatr Res 1997; 42: 169-173. (Pubitemid 27311336)
45. Venkitaraman A, Baatz J, Whitsett J, Hall S, Notter R,. Biophysical inhibition of synthetic phospholipid-lung surfactant apoprotein admixtures by plasma proteins. Chem Phys Lipids 1991; 57: 49-57.
46. Hamm H, Kroegel C, Hohlfeld J,. Surfactant: a review of its functions and relevance in adult respiratory disorders. Respir Med 1996; 90: 251-270. (Pubitemid 26169605)
47. Dargaville P, South M, McDougall P,. Surfactant abnormalities in infants with severe viral bronchiolitis. Arch Dis Child 1996; 75: 133-136. (Pubitemid 26276154)
48. Skelton R, Holland P, Darowski M, Chetcuti P, Morgan L, Harwood J,. Abnormal surfactant composition and activity in severe bronchiolitis. Acta Paediatr 1999; 88: 942-946. (Pubitemid 29448256)
49. Kerr M, Paton J,. Surfactant protein levels in severe respiratory syncytial virus infection. Am J Respir Crit Care Med 1999; 159: 1115-1118. (Pubitemid 29202544)
50. El Saleeby CM, Li R, Somes GW, Dahmer MK, Quasney MW, DeVicenzo JP,. Surfactant protein A2 polymorphisms and disease severity in a respiratory syncytial virus-infected population. J Pediatr 2010; 156: 409-414.
51. Puthothu B, Forster J, Heinze J, Heinzmann A, Krueger M,. Surfactant protein B polymorphisms are associated with severe respiratory syncytial virus infection, but not with asthma. BMC Pulm Med 2007; 7: 6.
52. Lahti M, Lofgren J, Marttila R, Renko M, Klaavuniemi T, Haataja R, Ramet M, Hallman M,. Surfactant protein D gene polymorphism associated with severe respiratory syncytial virus infection. Pediatr Res 2002; 51: 696-699. (Pubitemid 34547331)
53. Luchetti M, Casiraghi G, Valsecchi R, Galassini E, Marraro G,. Porcine-derived surfactant treatment of severe bronchiolitis. Acta Anaesthesiol Scand 1998; 42: 805-810. (Pubitemid 28332025)
54. Luchetti M, Ferrero F, Gallini C, Natale A, Pigna A, Tortorolo L, Marraro G,. Multicenter randomized, controlled study of porcine surfactant in severe respiratory syncytial virus-induced respiratory failure. Pediatr Crit Care Med 2002; 3: 261-268.
55. Tibby S, Hatherill M, Wright S, Wilson P, Postle A, Murdoch I,. Exogenous surfactant supplementation in infants with respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med 2000; 162: 1251-1256.
56. Bernhard W, Mottaghian J, Gebert A, Rau GA, von der Hardt H, Poets CF,. Commercial versus Native surfactants: surface activity, molecular components, and the effect of calcium. Am J Respir Crit Care Med 2000; 162: 1524-1533.
57. Ventre K, Haroon M, Davison C,. Surfactant therapy for bronchiolitis in critically ill infants. Cochrane Database Syst Rev 2006; CD005150.